All CIRM Grants

Institution Researcher name Grant Type Grant Title Award Value
Asterias Biotherapeutics Jane Lebkowski Strategic Partnership III Track A A Phase I/IIa Dose Escalation Safety Study of [REDACTED] in Patients with Cervical Sensorimotor Complete Spinal Cord Injury $14,323,318
Caladrius Biosciences, Inc. Robert Dillman Clinical Trial Stage Projects Tumor stem cell-targeted immunotherapy for metastatic melanoma –a randomized phase 3 clinical trial. $17,725,734
University of California, Davis Mehrdad Abedi Clinical Trial Stage Projects Stem Cell Gene Therapy for HIV Mediated by Lentivector Transduced, Pre-selected CD34+ Cells in AIDS lymphoma patients $8,435,822
University of California, San Francisco Katherine Nielsen Creativity Awards [REDACTED] SEP High School Intern Program $182,023
University of California, Los Angeles Donald Kohn Clinical Trial Stage Projects A Phase I/II, Non Randomized, Multicenter, Open-Label Study of G1XCGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease $7,083,364
Stanford University Judith Shizuru Disease Team Therapy Development - Research A monoclonal antibody that depletes blood stem cells and enables chemotherapy free transplants $19,068,382
City College Of San Francisco Carin Zimmerman Bridges Stem Cell Training Enhancement Program $2,732,437
Stanford University Helen Blau Early Translational III Local Delivery of Rejuvenated Old Muscle Stem Cells to Increase Strength in Aged Patients $1,825,920
University of California, Los Angeles Lili Yang Basic Biology V Differentiation of Human Hematopoietic Stem Cells into iNKT Cells $614,400
Stanford University Alan Cheng New Faculty Physician Scientist Enhancing hair cell regeneration in mouse and human inner ear $3,091,595
Sangamo BioSciences, Inc. Fyodor Urnov Strategic Partnership II A Treatment For Beta-thalassemia via High-Efficiency Targeted Genome Editing of Hematopoietic Stem Cells $2,760,540
Stanford University Paul Utz Creativity Awards [REDACTED] Program: Stem Cell & Developmental Biology Research Internships $357,864
University of California, San Francisco Tippi MacKenzie New Faculty Physician Scientist In Utero Embryonic Stem Cell Transplantation to Treat Congenital Anomalies $2,661,742
Cedars-Sinai Medical Center Shaomei Wang Late Stage Preclinical Projects IND-enabling study of subretinal delivery of human neural progenitor cells for the treatment of retinitis pigmentosa $4,954,514
University of California, Davis Gerhard Bauer Creativity Awards Internship at a Cutting Edge CIRM-funded Stem Cell Research Facility $299,928
University of California, Los Angeles Sophie Deng Early Translational II Regeneration of Functional Human Corneal Epithelial Progenitor Cells $1,524,947
San Diego State University Ralph Feuer Bridges CIRM Stem Cell Internship Program $4,211,606
University of California, Los Angeles Donald Kohn Disease Team Therapy Development III Clinical Trial of Stem Cell Gene Therapy for Sickle Cell Disease $13,145,465
University of California, San Diego Eric Ahrens Research Leadership Molecular Imaging for Stem Cell Science and Clinical Application $5,920,899
Stanford University Xinnan Wang Basic Biology V Misregulated Mitophagy in Parkinsonian Neurodegeneration $1,174,943
Stanford University Gary Steinberg Basic Biology V Paracrine and synaptic mechanisms underlying neural stem cell-mediated stroke recovery $1,178,370
Stanford University Vittorio Sebastiano Shared Labs Center for Human Embryonic Stem Cell Research and Education $3,434,600
Stanford University Irving Weissman Disease Team Research I Development of Therapeutic Antibodies Targeting Human Acute Myeloid Leukemia Stem Cells $18,759,276
Cedars-Sinai Medical Center Clive Svendsen Disease Team Therapy Development - Research Progenitor Cells Secreting GDNF for the Treatment of ALS $16,961,287
City of Hope John Zaia Strategic Partnership III Track A A Phase I, Open-Label Study to Assess the Safety, Feasibility and Engraftment of Zinc Finger Nucleases (ZFN) CCR5 Modified Autologous CD34+ Hematopoietic Stem/Progenitor Cells with Escalating Doses of Busulfan in HIV-1 (R5) Infected Subjects with Suboptim $5,583,438
Palo Alto Institute for Research and Education Thomas Rando Basic Biology V Molecular regulation of stem cell potency $966,510
Scripps Research Institute Jeanne Loring Shared Labs Center for hESC Research $3,725,070
Stanford University Anne Brunet Basic Biology IV Energy metabolism and aging pathways in human stem cell reprogramming and differentiation $1,414,044
City of Hope Karen Aboody Disease Team Research I Stem Cell-mediated Therapy for High-grade Glioma: Toward Phase I-II Clinical Trials $17,890,623
University of California, Santa Cruz David Haussler Research Training II CIRM Training Program in Systems Biology of Stem cells $4,591,616
Stanford University Anthony Oro Tools and Technologies III A Chromatin Context Tool for Predicting iPS Lineage Predisposition and Tissue Graftability $1,391,125
University of California, Berkeley David Schaffer Shared Labs Human Embryonic Stem Cell Shared Research Laboratory $1,688,129
University of California, San Diego Eric Adler Early Translational III Identification of Novel Therapeutics for Danon Disease Using an iPS Model of the Disease $1,701,575
University of Southern California Andrew McMahon Research Leadership Repair and regeneration of the nephron $5,672,206
Stanford University Fan Yang Tools and Technologies III Injectable Macroporous Matrices to Enhance Stem Cell Engraftment and Survival $1,438,200
University of California, San Francisco Ann Zovein New Faculty Physician Scientist Human endothelial reprogramming for hematopoietic stem cell therapy. $2,319,784
Calimmune, Inc. Geoff Symonds Disease Team Research I GENE-MODIFIED HEMATOPOIETIC STEM/PROGENITOR CELL BASED THERAPY FOR HIV DISEASE $8,278,722
Stanford University Sarah Heilshorn Tools and Technologies III Injectable Hydrogels for the Delivery, Maturation, and Engraftment of Clinically Relevant Numbers of Human Induced Pluripotent Stem Cell-Derived Neural Progenitors to the Central Nervous System $1,285,093
Sanford-Burnham Medical Research Institute Robert Wechsler-Reya Research Leadership The role of neural stem cells in cerebellar development, regeneration and tumorigenesis $5,226,050
University of Southern California Mark Humayun Disease Team Research I Stem cell based treatment strategy for Age-related Macular Degeneration (AMD) $18,904,916
Stanford University Irving Weissman Tools and Technologies III Identification and isolation of transplantable human hematopoietic stem cells from pluripotent cell lines; two steps from primitive hematopoiesis to transplantable definitive cells, and non-toxic conditioning of hosts for hematopoeitic stem cell transplan $1,341,403
University of California, Irvine Henry Klassen Disease Team Therapy Development - Research Retinal progenitor cells for treatment of retinitis pigmentosa $17,144,825
Stanford University Michele Calos Tools and Technologies II Site-specific integration of Lmx1a, FoxA2, & Otx2 to optimize dopaminergic differentiation $1,592,897
University of California, Los Angeles Zack Jerome Early Translational IV Stem Cell Programming With Chimeric Antigen Receptors to Eradicate HIV Infection $4,925,166
University of California, San Francisco Holger Willenbring Early Translational III Generation of safe and therapeutically effective human induced hepatocyte-like cells $1,544,170
University of California, Davis Alice Tarantal Shared Labs Translational Human Embryonic Stem Cell Shared Research Facility $1,728,111
University of California, Los Angeles Owen Witte Shared Labs CIRM Shared Research Laboratories $1,751,297
University of California, Los Angeles Dennis Slamon Disease Team Therapy Development III A Phase I dose escalation and expansion clinical trial in patients with advanced solid tumors $6,924,317
Salk Institute for Biological Studies Inder Verma Early Translational IV Development of a cell and gene based therapy for hemophilia $2,298,634
Cedars-Sinai Medical Center Barry Stripp Research Leadership Epithelial progenitors and the stromal niche as therapeutic targets in lung disease $4,841,830
Stanford University Hiromitsu Nakauchi Research Leadership Generation of functional cells and organs from iPSCs $5,436,308
University of California, San Diego Joseph Gleeson Tissue Collection for Disease Modeling CIRM Tissue Collection for Neurodevelopmental Disabilities $830,428
University of California, Los Angeles Gerald Lipshutz Early Translational IV Gene therapy-corrected autologous hepatocyte-like cells from induced pluripotent stem cells for the treatment of pediatric single enzyme disorders $1,801,629
University of California, Davis Emanual Maverakis New Faculty Physician Scientist Tunable hydrogels for therapeutic delivery of multipotent stem cells. $2,772,000
Cellular Dynamics International Thomas Novak hiPSC Derivation Generation and characterization of high-quality, footprint-free human induced pluripotent stem cell lines from 3,000 donors to investigate multigenic diseases $16,000,000
University of California, San Diego Catriona Jamieson Alpha Stem Cell Clinics Alpha Stem Cell Clinic for the Development of Regenerative Therapies $7,999,137
City of Hope John Zaia Alpha Stem Cell Clinics The Innovation-Alpha Clinic for Cellular Therapies (I-ACT) – A Program for the Development and Delivery of Innovative Cell-based Treatments and Cures for Life-threatening Diseases. $8,000,000
Gladstone Institutes Deepak Srivastava Early Translational III Direct Cardiac Reprogramming for Heart Regeneration $6,319,110
University of California, San Diego Kang Zhang Tissue Collection for Disease Modeling Generation of fibroblast cell lines in patients with common blinding eye diseases $1,034,425
University of California, Irvine Craig Walsh Early Translational III Multiple Sclerosis therapy: Human Pluripotent Stem Cell-Derived Neural Progenitor Cells $4,590,219
University of California, Los Angeles Leif Havton Tools and Technologies III Development of a Relevant Pre-Clinical Animal Model as a Tool to Evaluate Human Stem Cell-Derived Replacement Therapies for Motor Neuron Injuries and Degenerative Diseases $1,308,711
University of California, San Francisco Ophir Klein New Faculty Physician Scientist Stem cell therapy for inflammatory bowel disease $3,084,000
University of California, Irvine Peter Donovan Basic Biology V Non-invasive live imaging of stem cell signature metabolic states $540,480
University of California, San Francisco Andrew Leavitt Tools and Technologies III Small molecule tools and scale-up technologies to expand human umbilical cord blood stem and progenitor cells for clinical and research use $1,416,600
University of California, San Francisco Jacquelyn Maher Tissue Collection for Disease Modeling iPSC-derived Hepatocytes as Platforms for Research in Viral Hepatitis and Non-alcoholic Steatohepatitis $814,976
University of California, Los Angeles William Lowry Basic Biology III Molecular determinants of accurate differentiation from human pluripotent stem cells $677,115
California Institute for Biomedical Research Peter Schultz Preclinical Development Awards Development of a Chondrogenic Drug Candidate Targeting Cartilage-residing Mesenchymal Stem Cells for the Treatment of Osteoarthritis $2,306,703
University of California, Davis John Laird Disease Team Therapy Development - Research Phase I study of IM Injection of VEGF-Producing MSC for the Treatment of Critical Limb Ischemia $3,731,362
Scripps Research Institute Peter Schultz Early Translational II Cartilage Regeneration by the Chondrogenic Small Molecule PRO1 during Osteoarthritis $6,047,249
Stanford University Michele Calos Early Translational IV Engineered iPSC for therapy of limb girdle muscular dystrophy type 2B $1,876,253
Berkeley City College Barbara Des Rochers Bridges Specialty in Stem Cell Biology $2,735,987
Stanford University Alfred Lane Disease Team Research I iPS Cell-Based Treatment of Dominant Dystrophic Epidermolysis Bullosa $11,039,208
Stanford University Gary Steinberg Disease Team Research I Embryonic-Derived Neural Stem Cells for Treatment of Motor Sequelae following Sub-cortical Stroke $18,026,648
University of California, San Francisco Daniel Lim Tools and Technologies II Development and preclinical testing of new devices for cell transplantation to the brain. $1,795,891
Stanford University Matthew Porteus Preclinical Development Awards Pre-clinical development of gene correction therapy of hematopoietic stem cells for SCID-X1 $910,228
Sanford-Burnham Medical Research Institute Stuart Lipton Early Translational IV Programming Human ESC-derived Neural Stem Cells with MEF2C for Transplantation in Stroke $885,000
University of Southern California Mark Humayun Disease Team Therapy Development III Phase 1 Safety Assessment of CPCB-RPE1, hESC-derived RPE Cell Coated Parylene Membrane Implants, in Patients with Advanced Dry Age Related Macular Degeneration $17,128,661
University of California, San Diego Cornelis Murre Basic Biology V Epigenetic mechanisms that enforce pluripotency in embryonic stem cells $1,161,000
Stanford University Joachim Hallmayer Tissue Collection for Disease Modeling Induced pluripotent stem cells from children with autism spectrum disorders $530,265
California State Polytechnic University, Pomona Jill Adler-Moore Bridges Collaborative CIRM Bridges Program to Enhance Stem Cell Research Training and Education $3,213,701
University of California, San Diego Miles Wilkinson Basic Biology V New Regulators of Spermatogonial Stem Cells: RHOX Homeobox Transcription Factors $560,160
University of California, San Diego Douglas Galasko Tissue Collection for Disease Modeling Collection of skin biopsies to prepare fibroblasts from patients with Alzheimer's disease and cognitively healthy elderly controls $643,693
University of California, Riverside Prudence Talbot Shared Labs A Stem Cell Core Facility for Studying Human Embryonic Stem Cell Differentiation $1,679,818
University of California, San Diego Dianne McKay Basic Biology V Role of intracytoplasmic pattern recognition receptors in HSC engraftment $615,639
University of California, Los Angeles Antoni Ribas Disease Team Therapy Development - Research Genetic Re-programming of Stem Cells to Fight Cancer $19,875,776
ViaCyte, Inc. Howard Foyt Strategic Partnership I Preclinical and clinical testing of a stem cell-based combination product for insulin-dependent diabetes $10,075,070
University of California, Los Angeles Martin Martin Tools and Technologies II Pluripotent and Somatic Stem Cell Models to Study Inherited Diarrheal Disorders $1,783,250
ViaCyte, Inc. Howard Foyt Accelerated Development Pathway I Clinical Development of a Cell Therapy for Diabetes $16,603,160
San Francisco State University Carmen Domingo Bridges Bridges to Stem Cell Research $4,201,420
California State University, Northridge Cindy Malone Bridges Bridges to Stem Cell Research $3,936,573
University of California, Irvine Leslie Thompson Preclinical Development Awards A hNSC Development Candidate for Huntington’s Disease $4,951,623
Parkinson's Institute Birgitt Schuele Tools and Technologies II Editing of Parkinson’s disease mutation in patient-derived iPSCs by zinc-finger nucleases $1,327,983
University of California, Davis Vicki Wheelock Disease Team Therapy Development - Research MSC engineered to produce BDNF for the treatment of Huntington's disease $9,876,933
University of California, Davis Frederick Meyers Research Training II Stem Cell Training Program $5,822,412
University of California, Los Angeles Ali Nsair Basic Biology III Characterization and Engineering of the Cardiac Stem Cell Niche $1,163,618
Stanford University Joseph Wu Disease Team Therapy Development - Research Human Embryonic Stem Cell-Derived Cardiomyocytes for Patients with End Stage Heart Failure $19,942,877
Children's Hospital of Los Angeles Tracy Grikscheit New Faculty Physician Scientist The generation and expansion of tissue-engineered small intestine from human stem/ progenitor cells: a preclinical study of functional translation $3,146,160
University of California, San Diego Christian Metallo Basic Biology V Metabolic regulation of cardiac differentiation and maturation $1,124,834
University of California, Davis Nancy Lane Disease Team Therapy Development - Research Treatment of osteoporosis with endogenous Mesenchymal stem cells $19,999,867
Capricor, Inc Rachel Smith Disease Team Therapy Development - Research Allogeneic Cardiac-Derived Stem Cells for Patients Following a Myocardial Infarction $19,782,136

Pages